LINC01023: A Drug Target / Disease Biomarker (G100652853)

Target Name: LINC01023

NCBI ID: G100652853

LINC01023

Other Name(s): long intergenic non-protein coding RNA 1023 | HP07349 | Long intergenic non-protein coding RNA 1023

LINC01023: A Drug Target / Disease Biomarker

LINC01023 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the regulation of inflammation and immune responses.

One of the key functions of LINC01023 is its ability to interact with the immune system. LINC01023 has been shown to regulate the production of immune cells in the bone marrow, and it has also been shown to play a role in the regulation of the immune response to infection.

In addition to its role in the immune system, LINC01023 is also known to be involved in the regulation of inflammation. LINC01023 has been shown to reduce inflammation in the body, and it has been shown to have anti-inflammatory effects.

Despite its potential role in the immune system and inflammation, LINC01023 is not yet a drug target or biomarker. Further research is needed to fully understand its function and potential therapeutic uses.

In conclusion, LINC01023 is a protein that is expressed in various tissues of the body that plays a role in the regulation of the immune system and inflammation. Further research is needed to fully understand its function and potential therapeutic uses.

Protein Name: Long Intergenic Non-protein Coding RNA 1023

The "LINC01023 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01023 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets